COMP <GO>
ALNY vs UTHR // ALTMAN Z-SCORE & DEBT/EQUITY
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. United Therapeutics Corporation (NASDAQ) • 15-METRIC TALLY: ALNY 3
— UTHR 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: UTHR
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
balance-sheet
3.16
LAST: $596.13 (-0.43%) • MKT CAP: $25.68B
balance-sheet
22.52
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. UTHR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | UTHR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 87.90% | -6.10 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | 20.10% | +1.20 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | 12.5x | +29.90 | UTHR | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | 4.09% | -2.09 | UTHR | /fcf-yield <GO> |
| Operating Margin | 13.50% | 46.90% | -33.40 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 41.90% | -33.50 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | 10.60% | +54.60 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.16 | 22.52 | -19.36 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.8 | 68.6 | -42.80 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.95 | +0.05 | ALNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 17.8x | +44.50 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.10B | $25.68B | -$3.58B | UTHR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | UTHR REV | ALNY GROSS % | UTHR GROSS % | ALNY FCF | UTHR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $3.18B | 81.8% | 87.9% | $465.4M | $1.04B |
| FY 2024 | $2.25B | $2.88B | 86.4% | 89.2% | -$42.6M | $1.08B |
| FY 2023 | $1.83B | $2.33B | — | — | $21.9M | $873.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
UTHR // BETA 0.95